LCN2 and breast cancer: Bauer et al. 11 showed that in primary human breast cancer, NGAL expression was a predictor of poor prognosis, and suggested that the presence of NGAL may assist in risk assessment and identifying a subset of patients requiring more aggressive adjuvant therapy.